<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Ibrutinib is a novel drug used in haematological malignancies. Its use is associated with an increased risk of atrial fibrillation (AF), which, in turn, exposes patients to embolic risk, including stroke. Reducing this risk requires anticoagulant therapy which is a matter of concern in the context of the increased bleeding risk of patients with haematological malignancies. In this context the presence of thrombocytopenia related to haematological disorder, ibrutinib-anticoagulants and ibrutinib-platelets interactions contribute to the amplification of the problem. The correct assessment of the thrombosis vs. haemorrhage balance represents a significant challenge for the clinician.</p>
<p>In this paper we discuss practical issues related to anticoagulation in patients treated with ibrutinib and incident AF.</p>
</abstract>

Ibrutinib is a novel drug used in haematological malignancies. Its use is associated with an increased risk of atrial fibrillation (AF), which, in turn, exposes patients to embolic risk, including stroke. Reducing this risk requires anticoagulant therapy which is a matter of concern in the context of the increased bleeding risk of patients with haematological malignancies. In this context the presence of thrombocytopenia related to haematological disorder, ibrutinib-anticoagulants and ibrutinib-platelets interactions contribute to the amplification of the problem. The correct assessment of the thrombosis vs. haemorrhage balance represents a significant challenge for the clinician.
In this paper we discuss practical issues related to anticoagulation in patients treated with ibrutinib and incident AF.

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis

“Carol Davila” University of Medicine

Romanian Journal of Internal Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ibrutinib is a novel drug used in haematological malignancies. Its use is associated with an increased risk of atrial fibrillation (AF), which, in turn,...

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis

Publicado en línea: 26 ago 2021

Páginas: 270 - 277

Recibido: 13 mar 2021

DOI: https://doi.org/10.2478/rjim-2021-0015

Palabras clave
ibrutinib, atrial fibrillation, anticoagulation, thromboembolic prophylaxis, haemorrhagic risk

© 2021 Denisa-Corina Ciuculete et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Ibrutinib in patients with atrial fibrillation – the challenge of thromboembolic prophylaxis

Publicado en línea: 26 ago 2021

Páginas: 270 - 277

Recibido: 13 mar 2021

DOI: https://doi.org/10.2478/rjim-2021-0015

Palabras claveibrutinib, atrial fibrillation, anticoagulation, thromboembolic prophylaxis, haemorrhagic risk

© 2021 Denisa-Corina Ciuculete et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Palabras clave
ibrutinib, atrial fibrillation, anticoagulation, thromboembolic prophylaxis, haemorrhagic risk